HomeCompareALRN vs YUM

ALRN vs YUM: Dividend Comparison 2026

ALRN yields 94.79% · YUM yields 1.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALRN wins by $3.03M in total portfolio value
10 years
ALRN
ALRN
● Live price
94.79%
Share price
$2.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.14M
Annual income
$1,021,196.07
Full ALRN calculator →
YUM
YUM
● Live price
1.85%
Share price
$155.48
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.0K
Annual income
$39,957.33
Full YUM calculator →

Portfolio growth — ALRN vs YUM

📍 ALRN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALRNYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALRN + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALRN pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALRN
Annual income on $10K today (after 15% tax)
$8,056.87/yr
After 10yr DRIP, annual income (after tax)
$868,016.66/yr
YUM
Annual income on $10K today (after 15% tax)
$157.45/yr
After 10yr DRIP, annual income (after tax)
$33,963.73/yr
At 15% tax rate, ALRN beats the other by $834,052.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALRN + YUM for your $10,000?

ALRN: 50%YUM: 50%
100% YUM50/50100% ALRN
Portfolio after 10yr
$1.62M
Annual income
$530,576.69/yr
Blended yield
32.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

ALRN
Analyst Ratings
4
Buy
1
Hold
Consensus: Buy
Altman Z
-26.5
Piotroski
1/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+11.4% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALRN buys
0
YUM buys
0
No recent congressional trades found for ALRN or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALRNYUM
Forward yield94.79%1.85%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$3.14M$107.0K
Annual income after 10y$1,021,196.07$39,957.33
Total dividends collected$2.79M$80.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold

Year-by-year: ALRN vs YUM ($10,000, DRIP)

YearALRN PortfolioALRN Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$20,179$9,478.67$10,980$280.44+$9.2KALRN
2$39,467$17,875.42$12,185$435.72+$27.3KALRN
3$74,904$32,674.56$13,722$684.14+$61.2KALRN
4$138,103$57,956.24$15,773$1,090.14+$122.3KALRN
5$247,636$99,865.76$18,650$1,773.02+$229.0KALRN
6$432,328$167,356.66$22,921$2,966.37+$409.4KALRN
7$735,650$273,059.80$29,685$5,158.69+$706.0KALRN
8$1,221,388$434,242.66$41,216$9,453.02+$1.18MALRN
9$1,980,686$673,800.19$62,672$18,571.31+$1.92MALRN
10$3,140,530$1,021,196.07$107,016$39,957.33+$3.03MALRN

ALRN vs YUM: Complete Analysis 2026

ALRNStock

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Full ALRN Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this ALRN vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALRN vs SCHDALRN vs JEPIALRN vs OALRN vs KOALRN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.